Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Study unveils powerful strategy to rejuvenate effectiveness of CAR T cell therapy against glioblastoma

Study unveils powerful strategy to rejuvenate effectiveness of CAR T cell therapy against glioblastoma

Measuring tumor force offers new clues for brain cancer treatment

Measuring tumor force offers new clues for brain cancer treatment

New strategy enhances immunotherapy effectiveness against glioblastoma by utilizing gut microbes

New strategy enhances immunotherapy effectiveness against glioblastoma by utilizing gut microbes

Experimental medication sensitizes glioblastoma to treatment and blocks tumor spread

Experimental medication sensitizes glioblastoma to treatment and blocks tumor spread

FAU researchers secure key grants to target new gene in the fight against glioblastoma

FAU researchers secure key grants to target new gene in the fight against glioblastoma

Glioblastoma patients live longer with triple treatment strategy

Glioblastoma patients live longer with triple treatment strategy

Dual-target CAR T cell therapy shrinks tumors in aggressive brain cancer

Dual-target CAR T cell therapy shrinks tumors in aggressive brain cancer

Mass General Brigham researchers share cancer research discoveries at ASCO 2025

Mass General Brigham researchers share cancer research discoveries at ASCO 2025

New peptide therapy shows promise against glioblastoma recurrence

New peptide therapy shows promise against glioblastoma recurrence

Targeting astrocytes could boost immunotherapy effectiveness in glioblastoma

Targeting astrocytes could boost immunotherapy effectiveness in glioblastoma

New genetic test speeds up brain tumor diagnosis to just two hours

New genetic test speeds up brain tumor diagnosis to just two hours

Multiple laboratory techniques can provide a wealth of knowledge about brain cancer

Multiple laboratory techniques can provide a wealth of knowledge about brain cancer

RANBP2 identified as key regulator in the progression of multiple solid tumors

RANBP2 identified as key regulator in the progression of multiple solid tumors

ZIP4 protein identified as driver of glioblastoma aggression

ZIP4 protein identified as driver of glioblastoma aggression

Chimeric RNA offers new clues for tailoring prostate cancer therapies

Chimeric RNA offers new clues for tailoring prostate cancer therapies

New study sheds light on 3D gene hubs driving brain cancer

New study sheds light on 3D gene hubs driving brain cancer

Targeting PGM3 offers new hope against deadly brain tumor

Targeting PGM3 offers new hope against deadly brain tumor

Inherited mutations in healthy cells may contribute to cancer development

Inherited mutations in healthy cells may contribute to cancer development

Triple therapy reduces tumor burden and improves survival in glioblastoma models

Triple therapy reduces tumor burden and improves survival in glioblastoma models

Breakthrough in scalable nanoparticle manufacturing for cancer treatment

Breakthrough in scalable nanoparticle manufacturing for cancer treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.